trending Market Intelligence /marketintelligence/en/news-insights/trending/eY9B-eu-lHzvAyBLMj1Zag2 content esgSubNav
In This List

Medicure settles patent infringement case against India's Gland Pharma

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Medicure settles patent infringement case against India's Gland Pharma

Medicure Inc. settled an infringement case against Gland Pharma Ltd. regarding the patent rights of the drug Aggrastat.

Aggrastat, or tirofiban hydrochloride, is used to reduce blood clots in patients who face sudden blockage of the blood flow to their hearts and who have non-ST elevation acute coronary syndrome.

The settlement took place in the U.S. District Court for the District of New Jersey, wherein Gland acknowledged that Medicure's drug patent rights are valid, enforceable and infringed.

The case was filed by Medicure on Nov. 19, 2018, in response to Gland Pharma seeking the U.S. Food and Drug Administration's approval to market a generic version of Aggrastat before Medicure's patent had expired.

After the settlement, Medicure will now enter into a license agreement with Gland as the India-based pharmaceutical company aims to launch its generic product around March 1, 2023.

Gland Pharma is a generics drug maker 74%-owned by China's Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

Further settlement details were undisclosed.